SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Turning Point Therapeutics, Inc. (TPTX) .
Criteria proven by this page:
- VALUE (35/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Analyst consensus target $73.60 (-2.5% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 42/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TPTX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio100.01
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-5.79
Book Value / Share$0.00
Revenue / Share$0.75
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$73.60 (-2.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-1.11 |
$0.00 |
$-16.59M |
- |
| 2018 |
$-1.66 |
$0.00 |
$-24.79M |
- |
| 2019 |
$-2.99 |
$0.00 |
$-72.13M |
- |
| 2020 |
$-3.85 |
$25M |
$-157.29M |
-629.2% |
| 2021 |
$-5.79 |
$30.83M |
$-236.55M |
-767.3% |
